The FARINGOCAT study: rapid antigen detection testing in acute pharyngitis

Rapid antigen detection testing impact on antibiotic use in acute pharyngitis: FARINGOCAT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN23587778

Enrollment

552

Registered

2008-03-20

Start date

2008-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pharyngitis Respiratory Acute pharyngitis

Interventions

1. Rapid antigen detection (case group) 2. Usual antigen detection (control group) Treatment will be decided in both groups by the general practitioner. This treatment could be 'nothing', an anti-the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Men and women 14 to 60 years old 2. More than one acute pharyngitis symptom, i.e., fever, sore throat, tonsillar exudate, cervical adenopathy and absence of cough, which leads to a visit to the family practice

Exclusion criteria

Exclusion criteria: 1. Does not consent to participate 2. Patient is younger than 14 or older than 60 years old 3. Pharyngitis more than five times in year 4. Immunodepression: quimiotherapy, radiotherapy, active neoplasia, acquired immune deficiency syndrome (AIDS), corticoids, immunosuppressor treatment 5. Valve heart disease 6. Rheumatoid fever 7. Pharyngitis with previous treatment during 15 days or recurrence of symptoms during 4 weeks after 7 days of complete antibiotic treatment 8. Pharyngitis of diphtheria or gonococcica cause 9. Tonsillectomy

Design outcomes

Primary

Measure	Time frame
1. Proportion of inadequate antibiotic prescription in each group 2. Use of antibiotic treatment 3. Use of rapid antigen detection testing 4. Rapid antigen detection testing result 5. Culture result Outcomes will be measured at baseline and three weeks in all patients. If there is a problem, i.e., a secondary effect, then this may take longer.	—

Secondary

Measure	Time frame
1. Clinical symptoms of acute pharyngotonsillitis: fever, tonsillar exudate, cervical adenopathies, absence of cough, measured at baseline and at dates below 2. Age, measured at baseline 3. Antibiotic treatment, measured at baseline and at dates below 4. Specific antibiotic treatment, measured at baseline and at dates below 5. Treatment secondary effects, measured at baseline and at dates below 6. Days without working, measured at baseline and at dates below 7. Medical visits during the first month, measured at week three in all patients, at week four if necessary 8. Patient satisfaction, measured between 3 - 4 weeks after the second visit in one group of patients, between 5 - 7 months in another group of patients Outcomes will be measured at three weeks in all patients. If there is a problem, i.e., a secondary effect, then this may take longer.	—

Measure

Time frame

1. Clinical symptoms of acute pharyngotonsillitis: fever, tonsillar exudate, cervical adenopathies, absence of cough, measured at baseline and at dates below 2. Age, measured at baseline 3. Antibiotic treatment, measured at baseline and at dates below 4. Specific antibiotic treatment, measured at baseline and at dates below 5. Treatment secondary effects, measured at baseline and at dates below 6. Days without working, measured at baseline and at dates below 7. Medical visits during the first month, measured at week three in all patients, at week four if necessary 8. Patient satisfaction, measured between 3 - 4 weeks after the second visit in one group of patients, between 5 - 7 months in another group of patients Outcomes will be measured at three weeks in all patients. If there is a problem, i.e., a secondary effect, then this may take longer.

—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026